-
Study aim
-
Finding a cost-benefit , effective, painless, safe and satisfactory treatment for limited alopecia areata
-
Design
-
This is a phase 3 clinical trial, randomized, controlled and blinded study , which will be performed on 108 patients.
Patients will be classified randomly into 6 parallel groups (5 treatment groups and 1 control group). For randomization, the "permuted block randomization" method will be used.
-
Settings and conduct
-
Patients will be selected from Rasoul Akram Hospital dermatology clinic and the follow-up visits would be done in weeks 2 and 6.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: 1)Patients with localized areata alopecia of beard or scalp (<3 patches), 2) Not receiving any medication for areata alopecia for at least 1 month before the beginning of the study, 3) Signing an informed written consent.
Exclusion criteria: 1) Patients with extensive alopecia (> 3 patches). 2) Patients with any systemic disorder, ophthalmic pathology, other dermatological diseases, skin atrophy, or infection at the alopecic region. 3) Patients with allergy or hypersensitivity to any component of the treatment products. 4) Pregnant and lactating women
-
Intervention groups
-
Group 1: eyedrop Latanoprost 0.005%
Group 2: solution Minoxidil 5%
Group 3: eyedrop Latanoprost 0.005% and solution Minoxidil 5%
Group 4: solution Betamethasone 0.1% and solution Minoxidil 5%
Group 5: solution Betamethasone 0.1% and eyedrop Latanoprost 0.005%
Group 6 (control) : solution Betamethasone 0.1%
-
Main outcome variables
-
1) The severity of alopecia, before and after therapy, will be measured by the Severity of Alopecia Tool (SALT) score.
2)Patients' satisfaction with treatment.